Amgen 2Q net dips on higher research, other costs (Update)

July 30, 2013 by Linda A. Johnson
This March 1, 2005 file photo shows one of many buildings at Amgen's wooded, sprawling headquarters complex in Thousand Oaks, Calif., Amgen Inc. releases its quarterly earnings Tuesday, July 30, 2013. (AP Photo/Reed Saxon, File)

Amgen Inc. said Tuesday that its second-quarter profit dipped 1 percent as higher spending on research, production and other items offset rising sales of its medicines.

However, the results from world's biggest biotech drugmaker soared above Wall Street expectations and it raised its profit forecast significantly. The company releases its results after the stock market closes, and despite the impressive results, Amgen's stock fell $1.80, or 1.6 percent, to $109.40 in after-hours trading. The stock gave back most of the $1.83 it gained during the regular trading session.

The maker of osteoporosis drug Prolia and Enbrel for rheumatoid arthritis and skin disorders said second-quarter net income was $1.26 billion, or $1.65 per share, down from $1.27 billion, or $1.61 per share, a year earlier.

Excluding one-time items, Amgen said adjusted net income was $1.44 billion, or $1.89 per share, well above the $1.74 analysts were expecting.

Thousand Oaks, California-based Amgen said revenue rose 5 percent to $4.68 billion. Analysts surveyed by FactSet expected $4.49 billion.

"There are some questions about whether this can be done quarter in, quarter out," said Judson Clark, biotech analyst at Edward Jones.

Clark said that uncertainty might explain the drop in Amgen's stock after the results were announced, but he noted that Amgen often posts "stellar results" and they get shrugged off by investors. He said much of the earnings beat was driven by a very low tax rate, just 11.9 percent, which was partly offset by "suboptimal expense control."

Amgen noted during a conference call that operating expenses rose 8 percent in the quarter, mainly due to a 17 percent jump in research spending because multiple experimental drugs are now in the very expensive final stage of patient testing. However, production costs were up 7 percent and sales and administrative expenses rose 3 percent.

"We will remain disciplined and committed to maintaining our dividend," while looking for attractive acquisition prospects, CEO Robert A. Bradway told analysts on the call.

Amgen said its drug pipeline is progressing well, and it expects to announce key final-stage testing data on three experimental drugs in the first half of next year. That likely will enable the company to seek approval for them from regulators. The drugs are for malignant skin cancer, recurrent ovarian cancer and high LDL, or bad cholesterol, that doesn't respond to pills such as Lipitor.

Sales in the quarter were led Neulasta and Neupogen, for fighting infection in cancer patients, with their combined sales up 7 percent to $1.44 billion. Enbrel sales jumped 9 percent to $1.16 billion, but sales of anemia drug Aranesp slipped 2 percent to $524 million.

Two newer drugs, Prolia and Xgeva for preventing skeletal damage from solid tumors, saw their combined sales jump 46 percent, to $437 million. They contain the same active ingredient, but at different doses. Xgeva got approval for a second use, for treating giant cell tumors in bone, during the quarter.

Amgen raised its 2013 profit forecast to $7.30 to $7.45 per share, from the $7.05 to $7.35 per share it predicted in April. It also tweaked its revenue forecast, saying it now expects to hit "the upper end" of its January forecast of $17.8 billion to $18.2 billion in sales for 2013.

Explore further: Amgen 4Q profit drops 16 pct. on higher spending

Related Stories

Amgen 4Q profit drops 16 pct. on higher spending

January 23, 2013
Drugmaker Amgen Inc. on Wednesday posted a 16 percent drop in fourth-quarter profit, as higher costs for production, marketing, research and other items offset higher sales for many of its biologic medicines. The results ...

IBM 2Q beats Street despite revenue slip

July 17, 2013
(AP)—IBM said Wednesday that its second-quarter net income fell 17 percent as revenue slipped and it absorbed the cost of layoffs.

Generic competition cuts Merck's Q1 sales, profit

May 1, 2013
Drugmaker Merck & Co. is reporting lower first-quarter results and cutting its 2013 profit forecast by 15 cents a share. It also is announcing a huge share buyback, up to $15 billion worth of its stock.

J&J 2Q profit jumps on higher sales, lower charges

July 16, 2013
Health care giant Johnson & Johnson's second-quarter profit more than doubled, thanks to higher sales of medicines and medical devices as it recovers from recalls and manufacturing problems that cut into sales.

Sales disappoint, but tax gain lifts Amgen profit

April 23, 2013
Tax credits helped biotech giant Amgen report first-quarter earnings that beat Wall Street's expectations, but sales growth disappointed investors.

Recommended for you

Best of Last Year—The top Medical Xpress articles of 2017

December 20, 2017
It was a good year for medical research as a team at the German center for Neurodegenerative Diseases, Magdeburg, found that dancing can reverse the signs of aging in the brain. Any exercise helps, the team found, but dancing ...

Pickled in 'cognac', Chopin's heart gives up its secrets

November 26, 2017
The heart of Frederic Chopin, among the world's most cherished musical virtuosos, may finally have given up the cause of his untimely death.

Sugar industry withheld evidence of sucrose's health effects nearly 50 years ago

November 21, 2017
A U.S. sugar industry trade group appears to have pulled the plug on a study that was producing animal evidence linking sucrose to disease nearly 50 years ago, researchers argue in a paper publishing on November 21 in the ...

Female researchers pay more attention to sex and gender in medicine

November 7, 2017
When women participate in a medical research paper, that research is more likely to take into account the differences between the way men and women react to diseases and treatments, according to a new study by Stanford researchers.

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.